Hem › Akut myeloid leukemi › New York › New York City
Kliniska studier för Akut myeloid leukemi i New York City, NY
51 studier för Akut myeloid leukemi söker deltagare vid platser i och runt New York City (inom ca 30 miles). Öppna en studie för att se vem som kan delta och hur du kontaktar studieteamet.
Officiell studietext (engelska)
Rekryterar du till en studie? Visa den högst upp på sidan – $99 i 30 dagar →
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
RekryterarFas 2
- Mount Sinai Hospital, New York
- Memorial Sloan Kettering Cancer Center, New York
A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia
RekryterarFas 1
- Memorial Sloan Kettering Cancer Center, New York
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
RekryterarObservationsstudieFriska volontärer välkomna
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes
RekryterarFas 1
- Memorial Sloan Kettering Cancer Center, New York
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
RekryterarFas 1
- Memorial Sloan Kettering Cancer Center, New York
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
RekryterarFas 2
- Mount Sinai Hospital, New York
- Memorial Sloan Kettering Cancer Center, New York
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
RekryterarFas 3
- Memorial Sloan Kettering Cancer Center, New York
- New York Presbyterian - Weill Cornell, New York
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
RekryterarFas 2
- Memorial Sloan Kettering Cancer Center, New York
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
RekryterarFas 2
- Mount Sinai Hospital, New York
- Memorial Sloan Kettering Cancer Center, New York
A Study of CRD3874-SI in People With Leukemia
RekryterarFas 1
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
RekryterarFas 2
- Memorial Sloan Kettering Cancer Center, New York
A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib
RekryterarFas 1/2
- Memorial Sloan Kettering Cancer Center, New York
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
RekryterarFas 3
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
- Memorial Sloan Kettering Cancer Center, New York
- och 1 fler
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
RekryterarFas 1/2
- Montefiore Medical Center, New York
Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
RekryterarFas 2
- Weill Cornell, New York
Cord Blood Transplant in Adults With Blood Cancers
RekryterarFas 2
- Memorial Sloan Kettering Cancer Center, New York
Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML
RekryterarFas 1
- Memorial Sloan Kettering Cancer Center, New York
- Memorial Sloan Kettering Cancer Center, New York
- Montefiore Medical Center, New York
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
RekryterarFas 1/2
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
- Memorial Sloan Kettering Cancer Center, New York
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
RekryterarFas 3
- Columbia University Irving Medical Center, New York
- Memorial Sloan Kettering Cancer Center - New York, New York
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
RekryterarFas 3
- Icahn School of Medicine at Mount Sinai, New York
- Columbia University, New York
- Weill Cornell Medical Center, New York
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
RekryterarFas 1
- Memorial Sloan Kettering Cancer Center, New York
- Weill Cornell Medical College-NY Presbyterian Hospital, New York
ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies
RekryterarFas 1
- NYU Langone Health, New York
Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies
RekryterarFas 4
- New York Presbyterian Hospital-Columbia University Medical Center, New York
Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia
RekryterarFas 1
- Memorial Sloan- Kettering Cancer Center, New York
Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
RekryterarFas 1/2
- Research Site, New York
A Study of the Combination of Ivosidenib, Azacitidine, and Venetoclax Followed by Ivosidenib Alone in People With Acute Myeloid Leukemia
RekryterarFas 2
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
RekryterarFas 2
- Weill Cornell Medicine - New York Presbyterian Hospital, New York
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
RekryterarObservationsstudie
- New York University Langone Medical Center, New York
- New York Presbyterian Hospital at Cornell, New York
- Mount Sinai Medical Center - New York, New York
- och 3 fler
A Study of Revumenib and Mezigdomide in People With Leukemia
RekryterarFas 1/2
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia
RekryterarFas 1
- Memorial Sloan Kettering Cancer Center (All protocol activites), New York
A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML)
RekryterarFas 1
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
A Study of Natural Killer Cells in Combination With Atezolizumab in People With Acute Myelogenous Leukemia
RekryterarFas 1
- Memorial Sloan Kettering Cancer Center, New York
BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
RekryterarFas 1
- New York Medicine-New York-Presbyterian Hospital, New York
- Montefiore Medical Center - Montefiore Hospital, New York
Cord Blood Transplantation in Children and Young Adults With Blood Cancer
RekryterarFas 2
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
RekryterarFas 2/3
- Perlmutter Cancer Center - 34th Street, New York
- Icahn School of Medicine at Mount Sinai, New York
Imetelstat Combinations in Relapsed AML
RekryterarFas 1
- Icahn School of Medicine at Mount Sinai, New York
A Study of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher Risk Myelodysplastic Syndromes
RekryterarFas 1
- Icahn School of Medicine at Mount Sinai, New York
Safety and Proof-of-Concept Study of RPT1G in Adults With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes
RekryterarFas 1
- Memorial Sloan Kettering Cancer Center, New York
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
RekryterarFas 2
- Memorial Sloan Kettering, New York
A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias
RekryterarFas 1
- Memorial Sloan Kettering Cancer Center, New York
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
RekryterarFas 1
- New York - Presbyterian / Weill Cornell Medicine, New York
- Mount Sinai - Ruttenberg Treatment Center, New York
- Columbia University Medical Center, New York
Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders
RekryterarFas 2
- Memorial Sloan Kettering Cancer Center, New York
A Study of ADCLEC.syn1 in People With Acute Myeloid Leukemia
RekryterarFas 1
- Memorial Sloan Kettering Cancer Center, New York
A Study of Azacitidine and Venetoclax in People With Acute Myeloid Leukemia (AML)
RekryterarFas 2
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
RekryterarFas 1
- New York University, New York
Pharmacokinetic and Safety Study of MRX-2843 in Adolescents and Adults With Relapsed/Refractory AML, ALL, or MPAL
RekryterarFas 1
- Memorial Sloan Kettering Cancer Center, New York
A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
RekryterarFas 1
- Memorial Sloan Kettering Cancer Center, New York
Study of REM-422 in Patients With AML or Higher Risk MDS
RekryterarFas 1
- Memorial Sloan Kettering, New York
A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML)
RekryterarFas 1
- Weill Cornell Medical College - NewYork-Presbyterian Hospital, New York
Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML
RekryterarFas 2
- Laura & Isaac Pe lmutter Cancer Center at NYU Langone Health, New York
- Weill Cornell Medical College - New York - Presbyterian Hospital, New York
A Study of BTX-A51 in People With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
RekryterarFas 1
- Memorial Sloan-Kettering Cancer Center, New York
Akut myeloid leukemi-studier i andra städer
- Houston, TX85 studier
- Boston, MA44 studier
- Seattle, WA41 studier
- Baldwin Park, CA40 studier
- Columbus, OH35 studier
- Philadelphia, PA34 studier
- Durham, NC33 studier
- Atlanta, GA31 studier
- Tampa, FL29 studier
- Chicago, IL26 studier
- Portland, OR25 studier
- Washington, DC24 studier
Andra studier i New York City
- Bröstcancer136 studier
- Icke-småcellig lungcancer121 studier
- Cancer (alla typer)109 studier
- Prostatacancer103 studier
- Metastaserande cancer93 studier
- Kolorektal cancer78 studier
- Äggstockscancer69 studier
- Lungcancer60 studier
- Multipelt myelom60 studier
- Bukspottkörtelcancer60 studier
- Endometriecancer52 studier
- Hjärtsvikt51 studier
Från ClinicalTrials.gov, data hämtad 6 okt. 2026. Varje studie har egna kvalifikationskrav; studieteamet avgör vem som kan delta.